SI
CRSP icon

Stephens Inc’s CRISPR Therapeutics CRSP Stock Holding History

Stephens Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,752
Closed -$643K – 1189
2020
Q2 		$643K Buy
+8,752
New +$512K 0.01% 637

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Stephens Inc's CRSP Position: Q3 2020 in Review

Stephens Inc sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 8,752 shares — an estimated $643K sold.

Stephens Inc first reported a position in CRSP in Q2 2020 and held it in 1 quarter. The position peaked at $643K in Q2 2020. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Stephens Inc reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Stephens Inc sold 8,752 CRISPR Therapeutics shares in Q3 2020, an estimated $643K.
  • Stephens Inc first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 1 quarter.
  • Stephens Inc's CRISPR Therapeutics position peaked at $643K in Q2 2020.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Stephens Inc's 13F filing for Q3 2020, filed 13 Nov 2020.